Clofibrate: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
No edit summary
+sd
 
(7 intermediate revisions by 5 users not shown)
Line 1: Line 1:
{{short description|Chemical compound}}
{{Drugbox
{{Drugbox
| verifiedrevid = 460043574
| verifiedrevid = 460043574
Line 42: Line 43:
<!--Chemical data-->
<!--Chemical data-->
| C=12 | H=15 | Cl=1 | O=3
| C=12 | H=15 | Cl=1 | O=3
| molecular_weight = 242.698 g/mol
| smiles = Clc1ccc(OC(C(=O)OCC)(C)C)cc1
| smiles = Clc1ccc(OC(C(=O)OCC)(C)C)cc1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
Line 53: Line 53:


<!-- Society and culture -->
<!-- Society and culture -->
It was patented in 1958 by [[Imperial Chemical Industries]] and approved for medical use in 1963.<ref name=Fis2006>{{cite book |last1=Fischer |first1=Jnos |last2=Ganellin |first2=C. Robin |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=474 |url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA474 |language=en}}</ref> Clofibrate was discontinued in 2002 due to adverse effects.
It was patented in 1958 by [[Imperial Chemical Industries]] and approved for medical use in 1963.<ref name=Fis2006>{{cite book | vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=474 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA474 |language=en}}</ref> Clofibrate was discontinued in 2002 due to adverse effects.


==Complications and controversies==
==Complications and controversies==
It can induce [[syndrome of inappropriate antidiuretic hormone hypersecretion|SIADH]], syndrome of inappropriate secretion of [[vasopressin|antidiuretic hormone ADH]] (vasopressin). Clofibrate can also result in formation of cholesterol stones in the gallbladder.
It can induce [[syndrome of inappropriate antidiuretic hormone hypersecretion|SIADH]], syndrome of inappropriate secretion of [[vasopressin|antidiuretic hormone ADH]] (vasopressin). Clofibrate can also result in formation of cholesterol stones in the gallbladder.


The [[World Health Organization]] Cooperative Trial on Primary Prevention of [[Ischaemic Heart Disease]] using clofibrate to lower serum [[cholesterol]] observed excess mortality in the clofibrate-treated group despite successful cholesterol lowering (47% more deaths during treatment with clofibrate and 5% after treatment with clofibrate) than the non-treated high cholesterol group. These deaths were due to a wide variety of causes other than heart disease, and remain "unexplained".<ref>{{cite journal |author= |title=WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators |journal=Lancet |volume=2 |issue=8403 |pages=600–4 |date=September 1984 |pmid=6147641 |doi= 10.1016/s0140-6736(84)90595-6|url=}}</ref>
The [[World Health Organization]] Cooperative Trial on Primary Prevention of [[Ischaemic Heart Disease]] using clofibrate to lower serum [[cholesterol]] observed excess mortality in the clofibrate-treated group despite successful cholesterol lowering (47% more deaths during treatment with clofibrate and 5% after treatment with clofibrate) than the non-treated high cholesterol group. These deaths were due to a wide variety of causes other than heart disease, and remain "unexplained".<ref>{{cite journal | title = WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators | journal = Lancet | volume = 2 | issue = 8403 | pages = 600–4 | date = September 1984 | pmid = 6147641 | doi = 10.1016/s0140-6736(84)90595-6 | s2cid = 2473318 }}</ref>


==References==
== References ==
{{Reflist}}
{{Reflist}}


Line 66: Line 66:
{{PPAR modulators}}
{{PPAR modulators}}


[[Category:Fibrates]]
[[Category:2-Methyl-2-phenoxypropanoic acid derivatives]]
[[Category:Prodrugs]]
[[Category:Prodrugs]]
[[Category:Chloroarenes]]
[[Category:Chloroarenes]]
[[Category:Phenol ethers]]


{{cardiovascular-drug-stub}}
{{cardiovascular-drug-stub}}

Latest revision as of 14:44, 15 December 2022

Clofibrate
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • AU: B1
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • US: Discontinued
Pharmacokinetic data
Protein bindingVariable, 92–97% at therapeutic concentrations
MetabolismHydrolyzed to clofibric acid; hepatic glucuronidation
Elimination half-lifeHighly variable; average 18–22 hours. Prolonged in renal failure
ExcretionRenal, 95 to 99%
Identifiers
  • ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.010.253 Edit this at Wikidata
Chemical and physical data
FormulaC12H15ClO3
Molar mass242.70 g·mol−1
3D model (JSmol)
Boiling point148 °C (298 °F)
  • Clc1ccc(OC(C(=O)OCC)(C)C)cc1
  • InChI=1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3 checkY
  • Key:KNHUKKLJHYUCFP-UHFFFAOYSA-N checkY
  (verify)

Clofibrate (trade name Atromid-S) is a lipid-lowering agent used for controlling the high cholesterol and triacylglyceride level in the blood. It belongs to the class of fibrates. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It can increase the level of HDL as well.

It was patented in 1958 by Imperial Chemical Industries and approved for medical use in 1963.[1] Clofibrate was discontinued in 2002 due to adverse effects.

Complications and controversies[edit]

It can induce SIADH, syndrome of inappropriate secretion of antidiuretic hormone ADH (vasopressin). Clofibrate can also result in formation of cholesterol stones in the gallbladder.

The World Health Organization Cooperative Trial on Primary Prevention of Ischaemic Heart Disease using clofibrate to lower serum cholesterol observed excess mortality in the clofibrate-treated group despite successful cholesterol lowering (47% more deaths during treatment with clofibrate and 5% after treatment with clofibrate) than the non-treated high cholesterol group. These deaths were due to a wide variety of causes other than heart disease, and remain "unexplained".[2]

References[edit]

  1. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 474. ISBN 9783527607495.
  2. ^ "WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators". Lancet. 2 (8403): 600–4. September 1984. doi:10.1016/s0140-6736(84)90595-6. PMID 6147641. S2CID 2473318.
Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Clofibrate&oldid=1127581413"